LONDON, Feb 5 (Reuters) - British regulators have received
extra trial data from AstraZeneca that supports their
view that the COVID-19 vaccine developed with Oxford University
is effective in the elderly, a vaccines official said on Friday
Britain has been rolling out the shot among all age groups
after the Medicines and Healthcare products Regulatory Agency
(MHRA) was the first regulator to approve it in December, but
some other European countries have said more data is needed
before it is given to those over 65.
"Since (initial approval) we've seen more data coming
through from AstraZeneca as more people are completing the
trial, which highlights again that efficacy in the elderly is
seen, and there's no evidence of lack of efficacy," Munir
Pirmohamed, Chair of the Commission on Human Medicines’ COVID-19
Vaccines Benefit Risk Expert Working Group said at a MHRA news
briefing.
(Reporting by Alistair Smout; editing by William James)
Astrazeneca (AZN)
